These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 17215448

  • 1. The glycocalyx protects erythrocyte-bound tissue-type plasminogen activator from enzymatic inhibition.
    Ganguly K, Murciano JC, Westrick R, Leferovich J, Cines DB, Muzykantov VR.
    J Pharmacol Exp Ther; 2007 Apr; 321(1):158-64. PubMed ID: 17215448
    [Abstract] [Full Text] [Related]

  • 2. Fibrin affinity of erythrocyte-coupled tissue-type plasminogen activators endures hemodynamic forces and enhances fibrinolysis in vivo.
    Ganguly K, Goel MS, Krasik T, Bdeir K, Diamond SL, Cines DB, Muzykantov VR, Murciano JC.
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1130-6. PubMed ID: 16284278
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes.
    Murciano JC, Medinilla S, Eslin D, Atochina E, Cines DB, Muzykantov VR.
    Nat Biotechnol; 2003 Aug; 21(8):891-6. PubMed ID: 12845330
    [Abstract] [Full Text] [Related]

  • 5. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J, Aleem AM, Selman SH, Skrzypczak-Jankun E, Lysiak-Szydlowska W, Grafos N, Fryer HJ, Greenfield RS.
    Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
    [Abstract] [Full Text] [Related]

  • 6. Inhibitor-resistant tissue-type plasminogen activator: an improved thrombolytic agent in vitro.
    Shohet RV, Spitzer S, Madison EL, Bassel-Duby R, Gething MJ, Sambrook JF.
    Thromb Haemost; 1994 Jan; 71(1):124-8. PubMed ID: 8165630
    [Abstract] [Full Text] [Related]

  • 7. Characterization of a small molecule PAI-1 inhibitor, ZK4044.
    Liang A, Wu F, Tran K, Jones SW, Deng G, Ye B, Zhao Z, Snider RM, Dole WP, Morser J, Wu Q.
    Thromb Res; 2005 Jan; 115(4):341-50. PubMed ID: 15668194
    [Abstract] [Full Text] [Related]

  • 8. Tissue type plasminogen activator facilitates NMDA-receptor-mediated retinal apoptosis through an independent fibrinolytic cascade.
    Kumada M, Niwa M, Hara A, Matsuno H, Mori H, Ueshima S, Matsuo O, Yamamoto T, Kozawa O.
    Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1504-7. PubMed ID: 15790922
    [Abstract] [Full Text] [Related]

  • 9. Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis.
    van Veen SQ, Meijers JC, Levi M, van Gulik TM, Boermeester MA.
    Shock; 2007 May; 27(5):534-41. PubMed ID: 17438459
    [Abstract] [Full Text] [Related]

  • 10. The interaction between components of the fibrinolytic system and GPIb/V/IX of platelets thrombus formation in mice.
    Matsuno H, Kozawa O, Ueshima S, Matsuo O, Collen D, Uematsu T.
    Br J Pharmacol; 2000 Oct; 131(4):858-64. PubMed ID: 11030738
    [Abstract] [Full Text] [Related]

  • 11. Plasminogen activator inhibitor type 2 inhibits cell surface associated tissue plasminogen activator in vitro: potential receptor interactions.
    Lobov S, Croucher DR, Saunders DN, Ranson M.
    Thromb Haemost; 2008 Aug; 100(2):319-29. PubMed ID: 18690354
    [Abstract] [Full Text] [Related]

  • 12. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.
    Yasui H, Suzuki Y, Sano H, Suda T, Chida K, Dan T, Miyata T, Urano T.
    Thromb Res; 2013 Jul; 132(1):100-5. PubMed ID: 23611258
    [Abstract] [Full Text] [Related]

  • 13. Very long half-life plasminogen activator inhibitor type 1 reduces bleeding in a mouse model.
    Jankun J, Selman SH, Keck RW, Łysiak-Szydłowska W, Skrzypczak-Jankun E.
    BJU Int; 2010 May; 105(10):1469-76. PubMed ID: 19912209
    [Abstract] [Full Text] [Related]

  • 14. Transcriptional profiling after bile duct ligation identifies PAI-1 as a contributor to cholestatic injury in mice.
    Wang H, Vohra BP, Zhang Y, Heuckeroth RO.
    Hepatology; 2005 Nov; 42(5):1099-108. PubMed ID: 16250054
    [Abstract] [Full Text] [Related]

  • 15. Functional role of the fibrinolytic system in development of adipose tissue.
    Lijnen HR.
    Verh K Acad Geneeskd Belg; 2009 Nov; 71(3):101-13. PubMed ID: 20088250
    [Abstract] [Full Text] [Related]

  • 16. Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin.
    Nakamura R, Umemura K, Hashimmoto H, Urano T.
    Thromb Haemost; 2006 Apr; 95(4):637-42. PubMed ID: 16601834
    [Abstract] [Full Text] [Related]

  • 17. Modulation of sympathetic activity by tissue plasminogen activator is independent of plasminogen and urokinase.
    Schaefer U, Vorlova S, Machida T, Melchor JP, Strickland S, Levi R.
    J Pharmacol Exp Ther; 2007 Jul; 322(1):265-73. PubMed ID: 17429057
    [Abstract] [Full Text] [Related]

  • 18. Fibrinolytic proteins in human bile accelerate lysis of plasma clots and induce breakdown of fibrin sealants.
    Boonstra EA, Adelmeijer J, Verkade HJ, de Boer MT, Porte RJ, Lisman T.
    Ann Surg; 2012 Aug; 256(2):306-12. PubMed ID: 22797359
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity.
    Charlton PA, Faint RW, Bent F, Bryans J, Chicarelli-Robinson I, Mackie I, Machin S, Bevan P.
    Thromb Haemost; 1996 May; 75(5):808-15. PubMed ID: 8725728
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.